ProfileGDS5678 / 1420977_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 65% 70% 73% 73% 70% 65% 71% 70% 70% 70% 70% 70% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5594672
GSM967853U87-EV human glioblastoma xenograft - Control 23.9172765
GSM967854U87-EV human glioblastoma xenograft - Control 34.4114770
GSM967855U87-EV human glioblastoma xenograft - Control 44.8600173
GSM967856U87-EV human glioblastoma xenograft - Control 54.7236973
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.347570
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9449865
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.4434671
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3828970
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.4005770
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.3186370
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.385870
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.3895970
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4015571